Drug Development Congress
22nd-23rd April 2010, Copthorne Tara, Kensington, London, United Kingdom
Drug Development Congress is administered by Osney Media.
Speakers

Our carefully researched speaker programmes are further enhanced by the opportunity for the delegates and speakers to discuss topics of interest in more detail during panel discussions. This means that the attendees not only benefit from the expertise of the high level speaker panel but also that of the other delegates.

 

If you have a cutting edge case study or a presentation and would like to join the speaker panel at the 2nd Annual Drug Development Congress, please contact Chris Davies at c.davies@oxfordglobal.co.uk

 

Speakers already confirmed for the 2010 Congress:





Wolfgang M. Baiker, Corporate Head of Development, Boehringer Ingelheim
James Bailey, GSK Team Leader, Medicinal Chemsitry, GSK
Sophie Banzet, Head of Safety Science CNS, Roche
Mireille Cantarini, Internal Clinical genetics Expert, Astrazeneca
Annick Cauvin, Senior Principal Scientist, Toxicology, UCB
Gvido Cebers, Principal Scientist, CNSP Research Area Toxicologist, Global Safety Assessment, Astrazeneca
Dominique, Demolle, CEO, Aepodia
Lucette Doessegger, Global Head Safety Licensing and Early Development, Roche
Martin Elmlinger, Director Biomarkers, Nycomed
Angela, Flannery Director, R&D Science Policy, Astrazeneca
Dr. Thomas Herget, Senior Director R&D New Technology Evaluation Performance & Life Science Chemicals, Merck
Vicki Ikin, Clinical Biomarker Scientist Group Manager, Astrazeneca
Bahija Jallal, VP Translational Sciences, Medimmune
Jörg Kemkowski, Vice President, Head of Institute of Pharmcology and Preclinical Drug Safety (IPAS), Nycomed GmbH
Farhad Khan, Principal Scientist in Epidemiology, Novo Nordisk A/S
Michael, L. Lim, PharmD, Oncology Medicine Development Centre,
Roy Mansfield, Director Safety and Risk Management, Pfizer
Dr. Julian C. Matthews, Senior Lecturer in the School of Cancer and Imaging Sciences, University of Manchester
Howard Mellor, Pre-Clinical Safety Scientist, General Toxicology Sciences, Safety Assessment UK, Astrazeneca
Alan, Morrison VP International Regulatory Affairs, Amgen
David Nicholson, SVP Global Research, Schering Plough
Michael O'Connell, Director, Life Sciences, Clinical Practice, Spotfire, TIBCO Software INC.
Taoufik Outas, Senior Scientist - Exploratory Development Department, Astellas
Elke Persohn, Head of Cellular Imaging Group, Novartis
Stefan Platz, Head Toxicology and Global Head Early Safety, Hoffman la Roche
Marc Princivalle, Director of Toxicology, Research and Preclinical Development & Head of Preclinical Rish Assessment, EMEA, Stiefel (GSK)
Eugenii Rabiner, Director, Clinical Imaging Applications, GSK
Tino Rossi, VP Preclinical Drug Discovery & Enabling Technologies, Neurosciences CEDD, GlaxoSmithKline
Thomas Steinbach, Senior Director Safety Surveillance & Risk Management, Wyeth
Philippe Van der Auwera, Global Head of Safety, Roche
Jingsong Wang, Director Discovery Medicine & Clinical Pharmacology, Bristol Myers Squibb
Will Watson, Senior Partnering Director, Teva Innovative ventures
Agnes Westelinck. Regulatory Affairs, Roche
Home | About The Event |  | Event Format | Speakers | Delegates | Solution Providers | Media Partners | Press Centre | Venue | Organisers | Other Events | Contact | Book Online | 
© Drug Development Congress